Lotus Pharmaceutical (1795 TT): 3Q22 Review- Best-Ever Quarter, Aided by Oncology Drug Launch in US
In 3Q22, Lotus recorded 76% y/y and 85% q/q to NT$5.389 billion, driven by US launch of Lenalidomide capsules. Going ahead, growth will be mainly...
396 Views
Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
Lotus has already created a compelling position in ASEAN, which has been further augmented by oral oncology drug launch in Europe. New ownership...
234 Views
Lotus Pharmaceutical (1795 TT) Growth Story for Blood Cancer Drugs
Lotus’ profits will remain upbeat thanks to stable market share for its main product Suboxone and its anti-obesity drug business in South Korea....
231 Views